<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35596263</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1440-1746</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>20</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of gastroenterology and hepatology</Title>
          <ISOAbbreviation>J Gastroenterol Hepatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Prevalence and clinical features of patients with autoimmune pancreatitis and inflammatory bowel disease: A systematic review and meta-analysis.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jgh.15894</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND AIM" NlmCategory="OBJECTIVE">Autoimmune pancreatitis (AIP) and inflammatory bowel disease (IBD) are categorized into immune-mediated inflammatory disorders (IMIDs). While AIP is a pancreato-biliary IMID with an increased incidence and prevalence among patients with IBD, its features are still unclear. This systematic review and meta-analysis aims to assess the prevalence and clinical characteristics of AIP-IBD patients.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Electronic databases were searched to identify observational studies assessing AIP and IBD. The primary outcome was the prevalence of IBD among AIP patients, and vice versa. Secondary outcomes included clinical findings and outcomes of each IMID in AIP-IBD patients. The pooled rate of each outcome was determined using a random effects model.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">For primary outcomes, 40 observational studies with 4,031 AIP patients were included and the pooled prevalence of IBD was 10.5% (95% CI 7.2%-15.0%). Meanwhile, 5 studies with 10,551 IBD patients were included and the pooled prevalence of AIP was 0.6% (95% CI 0.2%-1.9%). For secondary outcomes, 53 observational studies with 469 AIP-IBD patients were assessed. The rates of type 2 AIP and ulcerative colitis were 79.2% (95% CI 69.1%-86.6%) and 74.8% (95% CI 68.2%-80.4%), respectively. We also demonstrated AIP-IBD patients were at a significant increased risk of AIP recurrence and colectomy compared with patients with either AIP or IBD (RR = 1.9, 95% CI 1.1-3.1 and P = 0.014 and RR = 3.7, 95% CI 1.9-6.9, P &lt;0.001, respectively).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our meta-analysis reported the prevalence of AIP-IBD patients and demonstrated patients with both IMIDs had a high risk of poor outcomes.</AbstractText>
          <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fukuda</LastName>
            <ForeName>Soma</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Akiyama</LastName>
            <ForeName>Shintaro</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0003-0727-7638</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tarakji</LastName>
            <ForeName>Ahmad</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Division of Gastroenterology, Hepatology and Motility, University of Kansas, KS, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamdeh</LastName>
            <ForeName>Shadi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Division of Gastroenterology, Hepatology and Motility, University of Kansas, KS, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Suzuki</LastName>
            <ForeName>Hideo</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsuchiya</LastName>
            <ForeName>Kiichiro</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Australia</Country>
        <MedlineTA>J Gastroenterol Hepatol</MedlineTA>
        <NlmUniqueID>8607909</NlmUniqueID>
        <ISSNLinking>0815-9319</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Autoimmune pancreatitis</Keyword>
        <Keyword MajorTopicYN="N">Crohnâ€™s disease</Keyword>
        <Keyword MajorTopicYN="N">Immune-mediated inflammatory diseases</Keyword>
        <Keyword MajorTopicYN="N">Inflammatory bowel disease</Keyword>
        <Keyword MajorTopicYN="N">Ulcerative colitis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>0</Hour>
          <Minute>33</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35596263</ArticleId>
        <ArticleId IdType="doi">10.1111/jgh.15894</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
